Tocilizumab Liquid
NDC Package 71124-0019-0
Package Information
Tocilizumab liquids is a medication used alone or with other medications to treat moderate to severe rheumatoid arthritis in adults. This formulation utilizes a liquid delivery system. Marketed by Samsung Biologics Co., Ltd., this product is identified by NDC 71124-0019.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 71124 - Samsung Biologics Co., Ltd.
- 71124-0019 -
- 71124-0019-0 - 2 kg in 1 BOTTLE
- 71124-0019 -
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 71124-0019-0 identifies a specific commercial package of 2 kg in 1 bottle of Tocilizumab (UNFINISHED drug), a bulk ingredient labeled by Samsung Biologics Co., Ltd.. This liquid is formulated for use and contains tocilizumab as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Samsung Biologics Co., Ltd. on October 26, 2021. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used alone or with other medications to treat moderate to severe rheumatoid arthritis in adults. It is also used to treat rheumatoid arthritis in children (such as systemic juvenile idiopathic arthritis-SJIA, polyarticular juvenile idiopathic arthritis-PJIA). It helps to reduce pain and swelling due to rheumatoid arthritis. Tocilizumab may also be used to treat a reaction (Cytokine Release Syndrome-CRS) caused by certain cancer treatments. Tocilizumab belongs to a class of drugs known as Interleukin-6 (IL-6) blockers. It works by blocking IL-6, a substance made by the body that causes swelling (inflammation).
How is this Samsung Biologics Co., Ltd. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 71124001900. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.